AI Article Synopsis
- Italy has the highest rates of hepatitis C virus (HCV) infection and liver cancer deaths in Europe, but new treatments have expanded access, with over 244,000 people treated.
- While HCV-related deaths are expected to drop by 75% by 2030, Italy is at risk of not eliminating HCV completely by that time.
- To improve HCV elimination efforts, recommendations include expanding screening to more populations, raising awareness, ensuring continued access to direct-acting antivirals, and customizing care for high-risk groups.
Article Abstract
Italy has had the highest prevalence of hepatitis C virus (HCV) infection and mortality from HCV-related liver cancer in Europe. Although direct-acting antivirals (DAA) were initially restricted to persons with advanced fibrosis, their use has since been extended to all infected individuals; more than 244 000 persons have been treated to date. HCV liver-related mortality is expected to decline by 75% by 2030, achieving the World Health Organization target for mortality. However, Italy risks failing to meet the overall goal of eliminating HCV infection by 2030. In this light, €71.5 million have been allocated for screening initially specific target populations (persons who inject drugs, prison inmates, and the 1969-1989 birth cohort). Herein, we outline the challenges and recommendations for how to move Italy toward HCV elimination, including expanding screening programs in other populations, increasing awareness through strategic communication, sustaining DAA access, and tailoring care models to meet the needs of key populations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/infdis/jiad038 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!